Pangaea Oncology S.A. is a medical services company specializing in precision oncology and personalized medicine based on genetic analyses. It provides a comprehensive range of services to cancer patients and pharmaceutical companies across Spain and other European Union countries, aimed at improving patient survival, treatment responses, and quality of life. The company operates through interrelated divisions, including a clinical care unit for patient treatment, a state-of-the-art laboratory offering molecular diagnostics such as mutation analysis in tumor tissue and blood, gene amplification, translocation testing, immunohistochemistry, and gene expression profiling. Additional services encompass clinical trials support, in vitro drug profiling with assays like MTT proliferation, western blotting, colony formation, migration, invasion, and gene silencing, as well as a Dx platform for companion diagnostic validation and ad-hoc R&D for diagnostics firms. Pangaea Oncology S.A. also features an R&D division developing diagnostic tools focused on predictive models in liquid biopsy, massive sequencing, and pre-clinical applications, alongside biomarker discovery for novel targeted therapy targets. Founded in 2006 and headquartered in Barcelona, Spain, it positions itself as a key player in precision oncology services in Southern Europe.